ANGLE plc reported its interim financial results for the six months ended June 30, 2025. The company recorded revenues of £0.796 million, a decrease from £1.034 million in the same period in 2024. The net loss for the period was £9.268 million, compared to a loss of £7.713 million in the previous year. Operating costs decreased to £6.754 million from £7.5 million. The comprehensive loss for the period was £7.161 million, compared to £7.875 million in the same period the previous year. In terms of operational updates, ANGLE plc has made significant progress with strategic collaborations. Post-period, the company signed its first large medtech company collaboration with Myriad Genetics and is advancing discussions with the UK NHS. Additionally, the company is progressing with clinical lab accreditation which will allow them to offer clinical services. ANGLE has also developed a proprietary workflow integrating its Parsortix system with Illumina's sequencing technology, enabling dual genomic profiling from a single blood sample. The company successfully completed three large pharma contracts and has ongoing discussions for further work. The cash and cash equivalents stood at £5.27 million, with additional funding being a key focus to extend the cash runway into Q1 2026.